Vitamin C Shows Survival Signal in Blood Cancers
A clinical trial links daily ascorbic acid to better survival in early hematologic malignancies, challenging simplistic views on low-cost nutrient therapies.
High-dose antioxidants frequently divide oncologists, yet controlled data continues to clarify where nutrients actually alter clinical trajectories. A clinical trial evaluating oral vitamin C supplementation in patients with precancerous blood conditions and early-stage hematologic malignancies revealed a measurable survival advantage and a lower incidence of severe adverse events in the supplemented group.
The mechanism relies on biochemical cofactor activity rather than generic free-radical scavenging. Ascorbate acts as a direct cofactor for TET2 enzymes, which govern DNA demethylation in hematopoietic stem cells. In individuals carrying loss-of-function TET2 mutations, supplemental vitamin C enhances residual enzyme activity, restoring normal cellular differentiation and suppressing malignant clonal expansion.
Do not treat this finding as permission to run blind self-supplementation with high-dose packets. Request a routine complete blood count alongside your next comprehensive metabolic panel, and discuss clonal screening with a physician before adjusting high-potency micronutrient regimens.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.